Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 25, Issue 30, Pages 4722-4729Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2007.12.2440
Keywords
-
Categories
Funding
- NCI NIH HHS [4 R37 CA11898, 5 P50 CA108786] Funding Source: Medline
- NINDS NIH HHS [5 P50 NS20023] Funding Source: Medline
Ask authors/readers for more resources
Purpose The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan. Patients and Methods This phase II trial included two cohorts of patients. The initial cohort, comprising 23 patients, received bevacizumab at 10 mg/kg plus irinotecan every 2 weeks. The dose of irinotecan was based on the patient's anticonvulsant: Patients taking enzyme- inducing antiepileptic drugs (EIAEDs) received 340 mg/m(2), and patients not taking EIAEDs received 125 mg/m(2). After this regimen was deemed safe and effective, the irinotecan schedule was changed to an accepted brain tumor regimen of four doses in 6 weeks, in anticipation of a phase III randomized trial of irinotecan versus irinotecan and bevacizumab. The second cohort, comprising 12 patients, received bevacizumab 15 mg/kg every 21 days and irinotecan on days 1, 8, 22, and 29. Each cycle was 6 weeks long and concluded with patient evaluations, including magnetic resonance imaging. Results The 6-month progression-free survival among all 35 patients was 46% (95% Cl, 32% to 66%). The 6-month overall survival was 77% (95% Cl, 64% to 92%). Twenty of the 35 patients (57%; 95% Cl, 39% to 74%) had at least a partial response. One patient developed a CNS hemorrhage, which occurred in his 10th cycle. Four patients developed thromboembolic complications (deep venous thrombosis and/or pulmonary emboli). Conclusion Bevacizumab and irinotecan is an effective treatment for recurrent glioblastoma multiforme and has moderate toxicity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available